title: [Inflammatory breast carcinoma: towards molecular characterization?].
abstract: Inflammatory Breast Carcinoma (IBC) is a rare but aggressive form of breast carcinoma. Characteristic clinical and pathological features are well documented. Pathological response to chemotherapy is currently the only identified prognostic factor. This high-grade tumor exhibits phenotypical features of an aggressive tumor: absence of hormonal receptors in 56 to 83% of cases, high proliferating index, p53 expressed in 30 to 69%, Immunohistochemistry (IHC) detection of HER2 over expression in 38 to 60%. Current work on IBC points out specific molecular mechanisms: adhesion molecules such as E-Cadherin, apomucin MUC1 and angiogenesis processes contribute to the IBC phenotype. So does a gene named WISP3. This gene has been recently cloned and sequenced. It has been shown to be lost in IBC and could control tumor growth, invasion, and angiogenesis. This paper summarizes current knowledge on IBC and describes a new basis for a molecular definition of IBC.
authors.affiliation: Département de BioPathologie, Institut Paoli-Calmettes, Marseille. jauffrete@marseille.fnclcc.fr
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Charafe-Jauffret
authors.forename: Carole
authors.initials: C
authors.lastname: Tarpin
authors.forename: Christophe
authors.initials: C
authors.lastname: Ginestier
authors.forename: François
authors.initials: F
authors.lastname: Bertucci
authors.forename: Frédérique
authors.initials: F
authors.lastname: Penault-Llorca
authors.forename: Luc
authors.initials: L
authors.lastname: Xerri
authors.forename: Daniel
authors.initials: D
authors.lastname: Birnbaum
authors.forename: Patrice
authors.initials: P
authors.lastname: Viens
authors.forename: Jacques
authors.initials: J
authors.lastname: Hassoun
authors.forename: Jocelyne
authors.initials: J
authors.lastname: Jacquemier
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry / Q000235:genetics / Q000473:pathology*; D055511:CCN Intercellular Signaling Proteins; D002277:Carcinoma / Q000737:chemistry / Q000235:genetics / Q000473:pathology*; D015815:Cell Adhesion Molecules / Q000032:analysis; D005260:Female; D005752:Gastric Mucins / Q000032:analysis / Q000235:genetics; D018734:Genes, erbB-2; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins; D018396:Mucin-1 / Q000032:analysis / Q000235:genetics; D009361:Neoplasm Invasiveness / Q000235:genetics; D009363:Neoplasm Proteins / Q000032:analysis* / Q000235:genetics; D009389:Neovascularization, Pathologic / Q000235:genetics; D010641:Phenotype; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D020741:rho GTP-Binding Proteins / Q000032:analysis / Q000235:genetics; D000075024:rhoC GTP-Binding Protein
chemical_list: D055511:CCN Intercellular Signaling Proteins; D015815:Cell Adhesion Molecules; D005752:Gastric Mucins; D018969:Insulin-Like Growth Factor Binding Proteins; D018396:Mucin-1; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D020741:rho GTP-Binding Proteins; D000075024:rhoC GTP-Binding Protein; C400081:CCN6 protein, human; C053366:apomucin; C066690:RHOC protein, human